Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way.
Last Closing Price
February 14, 2018
Jefferies, Cowen, Evercore ISI
To view the prospectus for Pieris Pharmaceuticals, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277